Core Insights - The biotechnology sector in the Hong Kong stock market has shown strong performance, with several stocks experiencing significant gains today, particularly药捷安康-B which surged over 30% [1] Stock Performance Summary - 药捷安康-B: Increased by 31.25%, latest price at 218.000, total market value of 86.524 billion, year-to-date increase of 1557.79% [2] - 康宁杰瑞制药-B: Increased by 7.15%, latest price at 14.680, total market value of 14.245 billion, year-to-date increase of 319.43% [2] - 帝王国际投资: Increased by 5.50%, latest price at 0.115, total market value of 0.0213 billion, year-to-date increase of 155.56% [2] - 映恩生物-B: Increased by 5.00%, latest price at 336.000, total market value of 29.58 billion, year-to-date increase of 255.18% [2] - 基石药业-B: Increased by 4.66%, latest price at 7.190, total market value of 10.612 billion, year-to-date increase of 212.61% [2] - 三叶草生物-B: Increased by 4.39%, latest price at 2.140, total market value of 2.776 billion, year-to-date increase of 787.97% [2] - 百奥塞图-B: Increased by 3.86%, latest price at 24.220, total market value of 9.673 billion, year-to-date increase of 184.94% [2] - 来凯医药-B: Increased by 3.71%, latest price at 14.540, total market value of 6.49217 billion, year-to-date increase of 55.18% [2] - 君实生物: Increased by 3.29%, latest price at 27.600, total market value of 28.337 billion, year-to-date increase of 138.34% [2] - MIRXES-B: Increased by 3.26%, latest price at 72.900, total market value of 20.145 billion, year-to-date increase of 212.88% [2]

Group 1 - Corning Pharmaceutical-B (09966.HK) experienced a rise of over 7%, with a current increase of 6.79%, trading at 14.63 HKD [1] - The trading volume reached 37.113 million HKD [1]

Core Viewpoint - 康宁杰瑞制药-B (09966) shares increased by over 7%, currently trading at 14.63 HKD with a transaction volume of 37.113 million HKD, following the announcement of a share buyback program [1] Group 1: Share Buyback Announcement - 康宁杰瑞制药 announced a share buyback of 400,000 shares for a total cost of 5.483 million HKD [1] - The company has a maximum buyback limit of 20 million HKD, authorized by the board based on a general mandate approved by shareholders at the annual general meeting on June 12, 2025 [1] Group 2: Upcoming Events - The European Society for Medical Oncology (ESMO) will take place from October 17 to 21 in Berlin, Germany, where the latest research abstracts will be presented [1] - A total of 23 studies from China, including key research on 康宁杰瑞's KN026, have been selected for presentation at the ESMO [1]

Group 1 - Corning Pharmaceutical-B (09966) saw a stock increase of over 7%, currently trading at 14.63 HKD with a transaction volume of 37.113 million HKD [1] - The company announced a share buyback of 400,000 shares for a total cost of 5.483 million HKD, as part of a broader authorization to repurchase shares up to a maximum of 20 million HKD [1] - The European Society for Medical Oncology (ESMO) conference will take place from October 17 to 21 in Berlin, with 23 research studies from China, including key studies like Corning's KN026, being presented [1]

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on October 16, 2025, with Xiaomi Group-W leading in terms of buyback amount and quantity [1] Group 1: Buyback Details - Xiaomi Group-W (01810) repurchased 4 million shares for a total of 192 million [1] - Mengniu Dairy (02319) repurchased 1 million shares for 14.44 million [2] - Yun Gongchang (N23027) repurchased 2.01 million shares for 8.19 million [2] Group 2: Cumulative Buyback Data - Xiaomi Group-W has a cumulative buyback of 16.59 million shares, representing 0.060% of total share capital [2] - Mengniu Dairy has a cumulative buyback of 17.32 million shares, representing 0.443% of total share capital [2] - Yun Gongchang has a cumulative buyback of 20.62 million shares, representing 4.483% of total share capital [2] Group 3: Other Notable Buybacks - Lianyi Rong Technology-W (09959) repurchased 2.39 million shares for 7.48 million, with a cumulative total of 60.47 million shares, representing 2.830% of total share capital [2] - Kangning Jiere Pharmaceutical-B (09966) repurchased 400,000 shares for 5.48 million, with a cumulative total of 801,000 shares, representing 0.083% of total share capital [2] - Guisheng Tongqiao-B (02190) repurchased 50,000 shares for 1.24 million, with a cumulative total of 330,350 shares, representing 1.009% of total share capital [2]

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966.HK) repurchased 400,000 shares on October 16, 2025, at a total cost of HKD 5.483 million, indicating a strategic move to enhance shareholder value [1][2]. Group 1: Share Buyback Details - The company repurchased shares at prices ranging from HKD 13.520 to HKD 13.820 per share [1]. - The closing price on the day of the buyback was HKD 13.700, reflecting a 2.54% increase in share price [1]. - The total trading volume for the day was HKD 35.6313 million [1]. Group 2: Year-to-Date Buyback Summary - Year-to-date, the company has conducted three buyback transactions, totaling 801,000 shares repurchased [2]. - The cumulative amount spent on buybacks this year is HKD 10.9358 million [2]. - Detailed buyback transactions include: - October 16: 400,000 shares at a maximum price of HKD 13.820 and a minimum price of HKD 13.520, costing HKD 5.483 million [2]. - October 14: 293,000 shares at a maximum price of HKD 13.830 and a minimum price of HKD 13.030, costing HKD 3.9669 million [2]. - October 13: 108,000 shares at a maximum price of HKD 13.800 and a minimum price of HKD 13.690, costing HKD 1.4860 million [2].

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) announced a share buyback plan, indicating confidence in its financial position and future growth potential [1] Summary by Category Company Actions - The company plans to repurchase 400,000 shares at a total cost of HKD 5.483 million, scheduled for October 16, 2025 [1]

康宁杰瑞制药-B(09966)发布公告，于2025年10月16日，该公司斥资548.3万港元回购40万股。 ...

格隆汇10月16日丨康宁杰瑞制药-B(09966.HK)公告，10月16日耗资548.3万港元回购40万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 康寧傑瑞生物製藥 呈交日期： 2025年10月16日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 09966 | 說明 | 普通股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | ...